Form 4: Stoke Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, sold common stock to cover tax liabilities from restricted stock unit vesting.
Summary
- Jason Hoitt, Chief Patient Officer of Stoke Therapeutics, Inc. (STOK), reported multiple sales of common stock.
- The sales occurred on March 17, 2026, and March 18, 2026.
- A total of 3,712 shares were disposed of across five separate transactions.
- The transactions were issuer-mandated sales to satisfy tax withholding liabilities related to the vesting and settlement of restricted stock units.
- The shares were sold at weighted average prices ranging from $31.2838 to $33.3754 per share.
- Following these transactions, Jason Hoitt directly beneficially owns 10,276 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sales were non-discretionary and solely for tax withholding purposes related to RSU vesting, a standard practice in executive compensation.
Positives
- The underlying vesting of restricted stock units indicates compensation for the Chief Patient Officer's performance.
Negatives
- The transaction resulted in a reduction of Jason Hoitt's direct beneficial ownership of common stock by 3,712 shares.
Industry Context
StockSavvy.ai notes that insider sales for tax withholding purposes are a common occurrence following the vesting of equity awards and are generally not indicative of a change in management's outlook on the company's prospects, unlike discretionary sales.
Stakeholder Impact
- Shareholders: Minimal direct impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or insider confidence.
- Employees: The vesting of restricted stock units and subsequent tax-related sales are part of standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 03/17/2026 | Transaction date for sales of 1,033 and 748 shares of common stock. |
| 03/18/2026 | Transaction date for sales of 1,762, 139, and 30 shares of common stock. |
| 03/19/2026 | Date the Form 4 was signed by Jonathan Allan, Attorney-in-Fact. |
Keywords
Stoke Therapeutics, STOK, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Jason Hoitt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.